RNTX — Rein Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1420565 ·
Last close
$0.36
Market Cap
$30.75M
52W High
$2.10
52W Low
$0.28
ADV30
743,853
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -6,999,000 -5,537,000 59,430,000 943,000 51,663,000
Jun 2026 0 — -6,076,000 -6,375,000 65,973,000 8,542,000 55,774,000
Mar 2026 0 — -5,230,000 -5,838,000 26,288,000 4,445,000 59,702,000
Dec 2025 0 — -3,959,000 -31,967,000 24,158,000 3,215,000 52,245,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-18,832,000
Investing CF
—
Financing CF
$56,774,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.78
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-413,484,000
Inventory
—
Receivables
—
ST Investments
$32,105,000
EBIT TTM
$-20,757,000
Pretax Income TTM
$-50,473,000
Interest Exp TTM
—
Analysts
2

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -21,931,000 -49,871,000 24,158,000 52,245,000 -28,087,000 -19,361,000
Dec 2024 0 -28,112,000 -62,883,000 62,190,000 52,803,000 9,387,000 -22,291,000
Dec 2023 0 -15,348,000 -15,732,000 106,008,000 99,121,000 6,887,000 -19,808,000
Dec 2022 0 -27,647,000 -27,329,000 22,007,000 3,384,000 18,623,000 -24,865,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-49,761,000
OpCashFlow TTM
—
Assets (Latest)
$65,973,000
Forward EPS
—

Peers — same industry

TickerNameMarket CapLastDaily %
NXTC NextCure, Inc. $30.68M $6.70 —
BCTX BriaCell Therapeutics Corp. $30.65M $3.51 —
NSRX Nasus Pharma Ltd $30.57M $2.61 —
TELO Telomir Pharmaceuticals, Inc. $31.17M $0.42 —
RLFTY MindMaze Therapeutics Holding SA $30.24M $0.18 —

News headlines (Yahoo Finance, 1h cache)

Rein reports early Phase II data for inhaled IPF drug
2026-11-17 10:08 · Yahoo
Rein Therapeutics Announces Preliminary Blinded Phase 2 RENEW Data Showing Encouraging Lung Function Trends in Patients with Idiopathic Pulmonary Fibrosis and Reports Third Quarter 2026 Financial Resu
2026-11-16 12:30 · Yahoo
Rein Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
2026-11-02 13:00 · Yahoo
Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 Congress
2026-09-04 12:00 · Yahoo
Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis
2026-08-20 12:00 · Yahoo
Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-14 10:44 · Yahoo
Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications
2026-08-04 12:00 · Yahoo
Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries
2026-07-21 12:00 · Yahoo
Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis
2026-04-29 12:00 · Yahoo
Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock
2026-05-01 00:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.